



Commonwealth of Massachusetts  
**MassHealth Drug Utilization Review Program**  
 P.O. Box 2586, Worcester, MA 01613-2586  
**Fax:** (877) 208-7428 **Phone:** (800) 745-7318

## Anticonvulsant Prior Authorization Request

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about anticonvulsants and the Pediatric Behavioral Health Medication Initiative, including PA requirements, a complete list of all behavioral health medications, and preferred products, can be found within the MassHealth Drug List at [www.mass.gov/druglist](http://www.mass.gov/druglist). The related PA form is available at: **Pediatric Behavioral Health Medication Initiative PA Request Form.**

### Member information

Last name \_\_\_\_\_ First name \_\_\_\_\_ MI \_\_\_\_\_  
 MassHealth member ID # \_\_\_\_\_ Date of birth \_\_\_\_\_  
 Gender (Check one.)  F  M Member's place of residence  home  nursing facility

### Medication information

**Medication requested** (Check one or all that apply.)

- |  |  |
|--|--|
| <input type="checkbox"/> Afinitor Disperz (everolimus tablets for oral suspension) | <input type="checkbox"/> lamotrigine orally disintegrating tablet (ODT), ODT starter kit |
| <input type="checkbox"/> Aptiom (eslicarbazepine)                                  | <input type="checkbox"/> lamotrigine tablet starter kit                                  |
| <input type="checkbox"/> Banzel (rufinamide)                                       | <input type="checkbox"/> Oxtellar XR (oxcarbazepine extended-release)                    |
| <input type="checkbox"/> Briviact (brivaracetam solution, tablet)                  | <input type="checkbox"/> pregabalin  |
| <input type="checkbox"/> clobazam suspension, tablet                               | <input type="checkbox"/> Qudexy XR (topiramate extended-release capsule)                 |
| <input type="checkbox"/> Diacomit (stiripentol)                                    | <input type="checkbox"/> Spritam (levetiracetam tablet for oral suspension)              |
| <input type="checkbox"/> Epidiolex (cannabidiol)                                   | <input type="checkbox"/> Sympazan (clobazam film)  |
| <input type="checkbox"/> Equetro (carbamazepine extended-release)                  | <input type="checkbox"/> tiagabine   |
| <input type="checkbox"/> everolimus 2.5 mg, 5 mg, 7.5 mg, 10 mg                    | <input type="checkbox"/> Trokendi XR (topiramate extended-release capsule)               |
| <input type="checkbox"/> Fycompa (perampanel)                                      | <input type="checkbox"/> vigabatrin  |
| <input type="checkbox"/> Lamictal XR starter kit, lamotrigine extended-release     | <input type="checkbox"/> Vimpat (lacosamide solution, tablet)                            |
|  | <input type="checkbox"/> Xcopri (cenobamate)   |

**Dose, frequency, and duration of medication requested** \_\_\_\_\_

Drug NDC (if known) or service code \_\_\_\_\_

**Indication** (Check all that apply.)

- |   |  |  |
|---|--|--|
| <input type="checkbox"/> Bipolar disorder                           | <input type="checkbox"/> Epilepsy associated with tuberous sclerosis complex | <input type="checkbox"/> Migraine prophylaxis                      |
| <input type="checkbox"/> Diabetic peripheral neuropathy             | <input type="checkbox"/> Fibromyalgia  | <input type="checkbox"/> Pain associated with trigeminal neuralgia |
| <input type="checkbox"/> Dravet syndrome                            | <input type="checkbox"/> Infantile spasms                                    | <input type="checkbox"/> Postherpetic neuralgia                    |
| <input type="checkbox"/> Epilepsy or seizure disorder<br>Type _____ | <input type="checkbox"/> Lennox-Gastaut syndrome                             | <input type="checkbox"/> Other (describe) _____                    |

Please list all other medications currently prescribed for the member for this indication.

Please indicate prescriber specialty below.

Neurology  Psychiatry  Other \_\_\_\_\_

If prescriber is not a specialist, please attach consult notes from specialist.

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician.

Is this member a referral candidate for care coordination?  Yes  No

If yes, MassHealth will offer care coordination services to this member. Please describe which additional behavioral health services would be beneficial.

---

**Section I. Please complete for all requests for epilepsy or seizure disorder, excluding lamotrigine agents.**

Please provide the following information regarding previous trials.\*

- |               |                    |               |
|---------------|--------------------|---------------|
| 1. Drug _____ | Dates of Use _____ | Outcome _____ |
| 2. Drug _____ | Dates of Use _____ | Outcome _____ |
| 3. Drug _____ | Dates of Use _____ | Outcome _____ |

\*Attach a letter with additional information regarding medication trials as applicable.

---

**Section II. Please also complete for requests for Equetro, Lamictal XR starter kit, lamotrigine extended-release, Oxtellar XR, Qudexy XR, Spritam, and Trokendi XR.**

For Lamictal XR starter kit, lamotrigine extended-release, and diagnoses other than epilepsy or seizure disorder, only question 1 is required.

1. Please provide medical necessity for the use of the requested formulation instead of the respective formulation(s) that is available without prior authorization.

2. Has the member been stabilized on the requested agent (any form)?  Yes  No

---

**Section III. Please also complete for requests for pregabalin.**

For requests for epilepsy or seizure disorder, please complete question 1. For requests for fibromyalgia, please complete questions 2 and 3. For requests for diabetic peripheral neuropathy or postherpetic neuralgia, please complete questions 3 and 4.

1. Has the member experienced an inadequate response or adverse reaction to other anticonvulsants?

Yes. Please complete Section I above.

No. Explain medical necessity for the use of pregabalin.

2. Has the member experienced an inadequate response (four weeks of therapy) or adverse reaction to a tricyclic antidepressant (TCA), an SSRI-type antidepressant, an SNRI-type antidepressant, or cyclobenzaprine?

Yes. Please describe trial(s) below.

Drug \_\_\_\_\_ Dates of Use \_\_\_\_\_ Outcome \_\_\_\_\_

No. Explain why a TCA, an SSRI and SNRI-type antidepressant, and cyclobenzaprine have not been tried.

3. Has the member experienced an inadequate response (two weeks of therapy at 1,200 mg/day) or adverse reaction to gabapentin?

Yes. Please describe trial below.

Dose and frequency \_\_\_\_\_ Dates of Use \_\_\_\_\_ Outcome \_\_\_\_\_

No. Explain why gabapentin has not been tried.

4. Has the member experienced an inadequate response (four weeks of therapy) or adverse reaction to a tricyclic antidepressant (TCA), duloxetine, lidocaine patch, or venlafaxine?

Yes. Please describe trial below.

Drug \_\_\_\_\_ Dates of Use \_\_\_\_\_ Outcome \_\_\_\_\_

No. Explain why a TCA, duloxetine, lidocaine patch, and venlafaxine have not been tried.

---

#### **Section IV. Please complete for requests for Diacomit.**

1. Has the member experienced an inadequate response or adverse reaction to other anticonvulsants?

Yes. Please complete Section I above.

No. Explain why other anticonvulsants have not been tried.

2. Will the requested agent be used in combination with clobazam?  Yes  No

---

#### **Section V. For requests for Epidiolex, please attach medical records supporting the diagnosis.**

---

#### **Section VI. Please complete for requests for lamotrigine ODT.**

1. Does the member have a medical condition in which they are not able to swallow pills?

Yes. Please describe. \_\_\_\_\_  No

2. Has the member experienced an inadequate response or adverse reaction to lamotrigine dispersible tablets?

Yes. Please describe trial below.

Dose and frequency \_\_\_\_\_ Dates of Use \_\_\_\_\_ Outcome \_\_\_\_\_

No. Explain why lamotrigine dispersible tablets have not been tried.

---

#### **Section VII. Please complete for all requests for non-preferred drug products if one or more preferred drug products have been designated for this class of drugs.**

If one or more preferred drug products have been designated for this class of drugs, and if you are requesting PA for a non-preferred drug product, please provide medical necessity for prescribing the non-preferred drug product rather than the preferred drug product.

---

#### **MassHealth Pediatric Behavioral Health Medication Initiative**

Please fill out all the sections below, as applicable, for pediatric members only. You may also use the Pediatric Behavioral Health Medication Initiative PA Request Form if the member is prescribed other behavioral health medications.

---

#### **Section I. Please complete for all requests for medications subject to the Pediatric Behavioral Health Medication Initiative for members < 18 years of age.**

Is the member currently in an acute care setting?

Yes (Inpatient)  Yes (Community Based Acute Treatment)

Yes (Partial Hospitalization)  No

For members who are in an acute care setting, please document the outpatient prescriber after discharge.

Prescriber name \_\_\_\_\_ Contact information \_\_\_\_\_

Has the member been hospitalized for a psychiatric condition within the past three months?

Yes. Please document dates of hospitalization within the past three months. \_\_\_\_\_

No

On the current regimen, is the member considered to be a severe risk of harm to self or others?

Yes. Please provide details. \_\_\_\_\_  No

For regimens including an antipsychotic, are appropriate safety screenings and monitoring being conducted (e.g., weight, metabolic, movement disorder, cardiovascular, and prolactin-related effects)?

Yes  No. Please explain. \_\_\_\_\_

Has informed consent from a parent or legal guardian been obtained?\*  Yes  No

Please indicate prescriber specialty below.

Psychiatry  Neurology  Other \_\_\_\_\_

Specialist consult details (if the prescriber submitting the request is not a specialist)

\_\_\_\_\_  
Name(s) of the specialist(s) \_\_\_\_\_ Date(s) of last visit or consult \_\_\_\_\_

Contact information \_\_\_\_\_

For mid-level practitioners (e.g., nurse practitioners, physician assistants), please provide the name and specialty of the collaborating physician.

\_\_\_\_\_  
Please document member custody status.

Parent/Guardian  Department of Children and Families (DCF)

Please document member placement status.

Home with Parent/Guardian  Foster Care  Residential Treatment Facility

Uncertain  Other \_\_\_\_\_

Please document agency involvement.

DCF  Department of Mental Health (DMH)  Department of Developmental Services (DDS)

Department of Youth Services (DYS)

Is the member/family currently receiving appropriate psychotherapeutic and/or community based services for the targeted clinical mental health related concerns (e.g., Applied Behavioral Analysis, Children's Behavioral Health Initiative, school interventions, specialized placement)?

Yes. Please document details of interventions below, if applicable.  No

\_\_\_\_\_  
Psychiatric care provided is coordinated with other psychotherapeutic and community based services.  Yes  No

\* Sample informed consent form available on the MassHealth PBHMI Information webpage. For additional information go to:  
<https://www.mass.gov/info-details/pediatric-behavioral-health-medication-initiative-pbhmi-information>

---

**Section II. Mood Stabilizer Polypharmacy. Complete this section for all members < 18 years of age, if request will result in prescription of three or more mood stabilizers for ≥ 60 days within a 90-day period.**

Please document complete treatment plan (include all mood stabilizing agents).

1. Mood stabilizer name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

2. Mood stabilizer name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

3. Mood stabilizer name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

4. Mood stabilizer name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_

5. Other(s) \_\_\_\_\_

Please document if monotherapy trials (include drug name, dates/duration of use, and outcome) with mood stabilizers were tried before prescribing polypharmacy with three or more mood stabilizers in this member.\*

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.

---

---

---

*\* Attach a letter with additional information regarding medication trials as applicable.*

---

**Section III. Mood Stabilizer Request for Members < six years of age (agents considered to be used only for seizure diagnoses are not included).**

Please document complete treatment plan (include all mood stabilizer agents with dose/frequency/duration and indication(s) for the requested medication(s)).

---

---

Please document any previous medication trial(s). Include the drug name, dates/duration of use, and outcome.\*

Please document clinical rationale for use of a mood stabilizer for this member < six years of age.

---

---

*\* Attach a letter with additional information regarding medication trials as applicable.*

---

**Section IV. Multiple Behavioral Health Medications. Complete this section for all members < 18 years of age if request will result in prescriptions of four or more behavioral health medications within a 45-day period. For a complete list of all behavioral health medications, please refer to the MassHealth Pediatric Behavioral Health Medication Initiative.**

Please document complete treatment plan (include all behavioral health agents and indication(s) for each medication(s)).

1. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
2. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
3. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
4. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
5. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
6. Medication name/dose/frequency \_\_\_\_\_ Indication \_\_\_\_\_
7. Other(s) \_\_\_\_\_

Please document monotherapy trials (include drug name, dates/duration of use, and outcome) tried before prescribing a polypharmacy regimen for this member.\*

---

---

---

Please document the treatment plans for medication regimen simplification (e.g., dose consolidation, frequency reduction) or medical necessity for continuation of a complex medication regimen.

---

---

---

*\* Attach a letter with additional information regarding medication trials as applicable.*

---

**Prescriber information**

Last name\* \_\_\_\_\_ First name\* \_\_\_\_\_ MI \_\_\_\_\_  
NPI\* \_\_\_\_\_ Individual MH Provider ID \_\_\_\_\_  
DEA No. \_\_\_\_\_ Office Contact Name \_\_\_\_\_  
Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
E-mail address \_\_\_\_\_  
Telephone No.\* \_\_\_\_\_ Fax No.\* \_\_\_\_\_  
*\* Required*

---

**Prescribing provider's attestation, signature, and date**

I certify under the pains and penalties of perjury that I am the prescribing provider identified in the Prescriber information section of this form. Any attached statement on my letterhead has been reviewed and signed by me. I certify that the medical necessity information (per 130 CMR 450.204) on this form is true, accurate, and complete, to the best of my knowledge. I understand that I may be subject to civil penalties or criminal prosecution for any falsification, omission, or concealment of any material fact contained herein.

Prescribing provider's signature (Signature and date stamps, or the signature of anyone other than the provider, are not acceptable.)

**Signature required** \_\_\_\_\_

Printed name of prescribing provider \_\_\_\_\_ Date \_\_\_\_\_